Galena Biopharma&#44&#59; Inc. | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (13)

View All

Latest Articles

About This Stock More About This Stock
Rxi Pharmaceuticals Offers Great Risk-Reward Scenario Before Major Catalysts
Article By: Terry Chrisomalis
Friday, November 14, 2014 11:05 AM EDT
Rxi Pharmaceuticals is extremely undervalued should approaching catalysts fulfill promise.
In this article: TKMR, RXII, RGLS
Read
RXi Pharmaceuticals Posts Positive Phase 2a 3-Month Results In Hypertrophic Scars
Article By: Terry Chrisomalis
Tuesday, October 7, 2014 3:13 PM EDT
This validation is important because now the company is at a reduced risk investment level.
In this article: TKMR, ARWR, RXII
Read
Rxi Pharmaceuticals Presents Preliminary Phase 2 Data In Hypertrophic Scars, Share Price Unfairly Punished
Article By: Terry Chrisomalis
Wednesday, September 10, 2014 9:10 PM EDT
Rxi Pharmaceuticals posts initial phase 2a preliminary data in hypertrophic scars.
In this article: RXII
Read
Rxi Pharmaceuticals Is Ready To Show The True Power Of Its Technology Platform
Article By: Terry Chrisomalis
Wednesday, September 3, 2014 9:15 PM EDT
Rxi Pharmaceuticals to Showcase phase 2a hypertrophic scar Results and other data
In this article: AGN, TKMR, ARWR, RXII
Read
Roche Wastes No Time, Acquires Intermune For $8.3 Billion Dollars
Article By: Terry Chrisomalis
Tuesday, August 26, 2014 4:19 PM EDT
Roche deal spurs merger and acquisition activity across the biotech industry.
In this article: RHHBY, ACHN, ITMN, ARWR, RXII
Read
Opko Health Posts Positive Phase 3 Results For Its Rayaldee Drug
Article By: Terry Chrisomalis
Wednesday, August 13, 2014 5:10 PM EDT
Opko Health Achieves Positive Phase 3 Results for Chronic Kidney Disease
In this article: OPK, RXII
Read
All Posts

Latest Tweets for $RXII

No tweets yet!

PARTNER HEADLINES